KR20190019446A - Composition for blocking AGEs production and promoting AGEs decomposition comprising Korthalsella japonica extracts - Google Patents

Abstract

The present invention relates to a composition for preventing or treating diseases related to inhibition of advanced glycation end-products (AGEs) production and promotion of AGEs decomposition containing a Korthalsella japonica extract as an active component. According to the present invention, the Korthalsella japonica extract has an effect of inhibiting AGEs production and has an effect of cutting cross-linking between AGEs and collagen, thereby being used for preventing or alleviating AGEs related diseases such as diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis or Alzheimer′s caused by AGEs accumulation.

Description

[0001] The present invention relates to a composition for inhibiting the formation of a final glycation end product and for promoting degradation, which comprises a camellia mist mistake extract,

The present invention relates to a composition for inhibiting the formation of advanced glycation end-products (AGEs) and accelerating the decomposition of camphor tree sprout ( Korthalsella japonica (Thunb.) Engl.) Extract as an active ingredient. More specifically, A composition for prevention or treatment of diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis, or Alzheimer caused by inhibition of the formation of final glycation products including camellia mistletoe extract and cross-linking cleavage between final glycation products and collagen or inhibition of skin aging And compositions for improvement.

The Maillard reaction (Glycation) is the reaction of an initial stage product, a shiff base, by the nonenzymatic reaction of the carbonyl of the reducing sugar with the free amino of the protein, lysine or arginine, ) And forming brown irreversible final glycation end-products (AGEs) through a series of complex reactions such as condensation, re-dislocation, oxidation, cleavage, and cyclization.

This unreversible reaction product, a final glycation product, is not degraded once it is formed, but is cross-linked with lens protein, collagen, etc., accumulated in the skin or tissue, and abnormally changes its structure and function, It is known to be involved. In particular, many studies have reported that end glycated products are closely related to the progress of various diseases associated with aging such as diabetic complications, arteriosclerosis, end stage renal failure, rheumatoid arthritis, Alzheimer's, skin wrinkle formation (Semin Nephrol 2007 Mar; 27 (2): 130-43; and Curr Alzheimer Res. 2004 Feb; 1 (1): 39-46)

Among them, diabetic complications are well known as a representative disease associated with the final glycation end product. Diabetes mellitus is a typical chronic disorder characterized by insulin secretion and activity in the body. It is a chronic disease with a blood glucose level of 126 mg / dL or more after 8 to 12 hours of fasting, or 2 hours after glucose intake Is diagnosed as diabetes mellitus when measured at 200 mg / dL or more, and the highest risk of diabetes mellitus is complication due to hyperglycemia.

One of the factors promoting diabetic complications is the nonenzymatic cross-linking of proteins or lipids and proteins in the sugar and blood vessel walls. Normally normal cross-linking of intravascular collagen occurs only at specific sites of the N- and C-termini, but cross-linking with collagen by the final glycosylation occurs randomly at all sites and forms abnormal cross-linking. These abnormal cross-linkages, once formed, are not degraded in spite of normal recovery of blood glucose, accumulate in tissues during protein survival and act as a pathogen of neurovascular dysfunction, leading to diabetic retinopathy, diabetic cataract, diabetic nephropathy Causes fatal chronic diabetic complications.

Studies have also been reported that the final glycation end product is associated with Alzheimer's outbreak. Alzheimer's disease (AD) is a syndrome caused by brain disease, usually chronic and progressive, and refers to a multiple disorder of brain function, including memory, thinking, learning, language, and judgment.

The cause of Alzheimer's disease is not precisely known, but it is closely related to aging. It is presumed that the main cause is the accumulation of β-amyloid protein in the brain and aggregation. Previous studies have shown that, under normal physiological conditions, beta amyloid aggregates slowly, while AGE-modified beta-amyloid is rapidly aggregated by cross-linking with the final glycation end product (Neurobiology, 91 , 4766-4770,1994).

In addition, abnormal cross-linking of the final glycation end product with collagen is closely related to skin aging. Skin aging can be broadly classified into endogenous aging and extrinsic aging. Endogenous aging is a natural aging phenomenon caused by aging. It is affected by genes. Exogenous aging is an aging phenomenon caused by external factors such as ultraviolet rays, smoking and environmental pollution. It is also known as photoaging.

The main appearance change of skin aging is wrinkle formation due to structural change of dermis and decrease of skin elasticity. Collagen is a substance that constitutes 90% of the skin's dermis and is the main ingredient that gives skin elasticity. Skin wrinkles occur when collagen structure collapses. Collagen with a relatively long half-life easily undergoes glycosylation reaction and cross-linking of collagen with final glycosylated product causes skin elasticity to be reduced and wrinkle to promote skin aging. Previous studies have shown that abnormal structural changes were observed in the collagen microfilaments of rats when the final glycosylated product was present at increased concentrations (Odetti P, Aragno I, et al. Gerontology, 1998, 44 (4 ); 187-91). Another change in the appearance of aging skin is senility spots. It is known that senile spots are caused by various factors, and are known to be closely related to the accumulation of final glycation products.

As such, the final glycation products are associated with various diseases. Therefore, many advanced countries including Korea are investing heavily in the research and development of materials capable of inhibiting the final glycation end products or decomposing the final glycation end products. In particular, as interest in safe materials that can minimize side effects has increased recently, development of materials based on natural materials is becoming very important.

Mistletoe is a symbiotic plant belonging to the dwarf, which is a parasitic plant which is parasitic on tree branches or shrub branches and which produces photosynthesis by itself to produce chlorophyll. It has various names such as parasitic necks, gigas, parasites, mistletoe and viscum. It is a mixed plant.

In Korea, Viscum coloratum (Komarov) Nakai f. coloratum], red mistletoe [ Viscum coloratum (Komarov) Nakai f. ( Loranthus tanakae Franch. et Sav.) and Oakill mistletoe ( Taxierus yadoriki (Sieb. ex Maxim.)), three taxa and rubroaurantiacum (Makino) Kitagawa and Korthalsella japonica (Thunb.) Engl. ) Danser] such as the combined two taxa and the second and fourth speed 5 taxa distribution (Korean J. Pl. taxon. 4 myeong outer gimchansu, Korean mistletoe (Viscum, Korthalsella, Loranthus and Taxillus) classification and ecological Study of. 43 (2): 81-89 (2013)).

Among them, Camellia japonica is native to the southern part of Korea and Jejudo. It is a feature that the leaf is degenerated and attached like a protrusion between the nodes, and the part of the flower does not fall off. It is distinguished from mistletoe.

Related to the efficacy of the camellia mistletoe described in Korean Patent No. 10-1599458, a composition for preventing or treating skin inflammation comprising an alcohol extract of Camellia japonica (Thunb.) Engl) Patent No. 10-2008-0107922 relates to a method for preparing a mistletoe extract and a composition for enhancing memory or prevention of dementia including a mistletoe extract, wherein a viscum album and a Korean mistletoe extract ( Viscum album var. Coloratum) Beta-amyloid (Aβ), one of the causative agents of neurodegenerative diseases, has the activity of alleviating the toxicity of nerve cells, as well as the use of scopolamine and beta amyloid- Water Maze Model, which shows the effect of improving memory, Patent Publication No. 10-2015-0010414 discloses a mistletoe (Viscum album var. Coloratum) a wherein a protein having the activity to diabetes on antidiabetic mistletoe extract containing as an active ingredient, wherein the European mistletoe in mistletoe Viscum album derived from Loranthaceae, Viscum album var. Mistletoe growing in East Asia . Korean Patent No. 10-1685829 discloses a method for preparing a fermented product of a mistletoe extract having enhanced antioxidant activity. In this case, the mistletoe (Loranthaceae) is a perennial plant parasitic to oak, To which the plant belongs. Japanese Laid-Open Patent Application No. 2013-184974 discloses a medicament containing a plant belonging to the genus Astilbe and / or a plant belonging to Camellia camellia as an active ingredient, a mailer reaction inhibitor, a glycogen production inhibitor or AGEs And Korean Patent Laid-Open No. 10-2010-0047253 discloses a substance which promotes the desulfurization of AGEs or promotes the reversal of the Maillard reaction on AGEs as Phoradendron piperoides The mistletoe is presented. There is no report yet on the effect of the camellia mistletoe ( Korthalsella japonica (Thunb.) Engl) on the inhibition of AGE formation and the prophylactic or therapeutic effect of diabetes complications, Alzheimer's disease and skin aging.

Korean Patent Publication No. 10-2006-0066180 discloses a Korean mistletoe ( Korean Viscum album , var. coloratum), and discloses a cosmetic composition for whitening whiteness and wrinkle-reducing functional components of mistletoe and tail mistletoe. In the study, the Korean oak mistletoe ( Viscum album var. coloratum) and Loranthus tanakae (anti-oxidant, whitening and wrinkle). However, it has been reported that Kortalsella japonica (Thunb. Engl) There is no.

Accordingly, the present invention confirms the inhibition of the final glycosylation and the final glycosylated product cross-linking cleavage of the extract of Korthalsella japonica (Thunb.) Engl, and confirms that the extract is useful for the treatment of diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis, Related diseases such as Alzheimer's disease and the like, and for preventing or treating skin aging.

Accordingly, a technical problem to be solved by the present invention is to provide a pharmaceutical composition for preventing or treating a disease associated with promotion of inhibition and decomposition of final glycation end products including extracts of Camellia japonica (Thunb.) Engl .

Another technical problem to be solved by the present invention is to provide a cosmetic composition for inhibiting or improving skin aging by inhibiting the production of a final glycosylation product including a Korthalsella japonica (Thunb.) Engl extract and accelerating decomposition .

Another object of the present invention is to provide a food composition for preventing or ameliorating a disease associated with promotion of the inhibition of the formation of the final glycation end product and the degradation including the extract of Korthalsella japonica (Thunb.) Engl) .

In order to solve the above-mentioned technical problems, the present invention provides a method for the treatment and / or prophylaxis of diabetic complications comprising an extract of Camellia japonica (Thunb.) Engl as an active ingredient, a compound selected from the group consisting of arteriosclerosis, renal failure, rheumatoid arthritis and Alzheimer And a pharmaceutical composition for preventing or treating the above diseases.

Also, in order to solve the above-mentioned other technical problems, the present invention provides a cosmetic composition for prevention or improvement of skin aging comprising an extract of Camellia japonica (Thunb.) Engl as an active ingredient.

Also, in order to solve the above-mentioned technical problem, the present invention provides a pharmaceutical composition comprising diabetic complications, antherosclerosis, renal insufficiency, rheumatoid arthritis and Alzheimer's disease, which comprise an extract of Camellia japonica (Thunb.) Engl as an active ingredient At least one disease selected from the group or a food composition for preventing or ameliorating skin aging.

The camellia tree mistletoe ( Korthalsella japonica (Thunb.) Engl), which is an effective ingredient of the composition for inhibiting the formation of the final glycation end product and promoting degradation of the present invention, is an evergreen parasite which is naturally occurring in the temperate regions of 700 m or less in altitude such as Mokpo, Jeju Island, It is 5 ~ 30cm high and has green hairs. There are no hairs, many joints are divided, and the nodes are flat. There are many nodes of escaping type with a length of 2-20㎜. The leaves are degenerated and scaly, and they are like ridges on the upper end of the nodule. The leaves are degenerated and small and run like nods on the upper end of the nodule. Flower is bloomed in April-May, with a diameter of less than 1mm. It has 5-6 hairs per section, no peduncle, and the anvil is divided into 3 pieces. The nest is subordinate. Fruits are berries, ripening in October-December, 2mm in diameter, wide elliptical, with style at the end, 1 seed, and protruding from the skin.

In the present invention, the camellia mistletoe extract can be obtained using an extraction method and an extraction solvent known in the art, and preferably water, anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, Butanol, etc.), a mixed solvent of the lower alcohol and water, acetone, ethyl acetate, chloroform or 1,3-butylene glycol as an extraction solvent.

In addition, the camellia mistletoe extract can be obtained through a conventional purification process in addition to the extraction method using the above-mentioned extraction solvent. For example, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographies (made for separation by size, charge, hydrophobicity or affinity) Through the obtained fractions, a Camellia maculicum extract can also be obtained.

According to one specific embodiment of the present invention, the Camellia pallidum outpastes are each shaved and crushed, and then 0.5 to 20 times, preferably 1 to 15 times the weight of the dried sample, water such as C1 To C4 lower alcohols or mixtures of water and ethanol at a mixing ratio (kg / l) of 1: 0.1 to 1:10, preferably 1: 0.2 to 1: 9, at room temperature for about 0.5 to 48 hours , Preferably for 1 to 30 hours, using an extraction method such as stirring extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction, preferably by ultrasonic extraction and then filtration and concentration under reduced pressure or drying, Wood mistletoe extract can be obtained.

In the present invention, the camellia mistletoe extract contains all extracts, fractions and tablets obtained in each step of extraction, fractionation or purification, their diluted solutions, concentrates or dried products.

According to a specific embodiment of the present invention, the camellia mistletoe extract has the effect of inhibiting the production of the final glycation end product and cleaving the cross-linking of the collagen with the final glycation end product, thereby preventing diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis, Or Alzheimer ' s disease, and has an effect of inhibiting and improving skin aging.

According to one preferred embodiment of the present invention, the present invention provides a method for preventing or treating diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis or Alzheimer's disease, which comprises extract of Korthalsella japonica (Thunb.) Engl as an active ingredient As a pharmaceutical composition, the present invention relates to a composition characterized in that the disease is prevented or treated by inhibiting the formation of the final glycation end product by camellia mistletoe extract and accelerating the degradation.

The pharmaceutical composition of the present invention may contain 0.001 to 10% by weight, preferably 0.001 to 5% by weight, based on the total composition, of camellia mistletoe extract. When the content is less than 0.001% by weight, the effect of inhibiting the formation of AGEs and decomposing activity is too weak. When the content is more than 10% by weight, have.

The pharmaceutical composition according to the present invention may further include components commonly used in pharmaceutical compositions in addition to the camellia mistletoe extract. For example, lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, suspending agents, preservatives and carriers.

Suitable carriers for such pharmaceutical compositions include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, , Syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, but are not limited thereto. Suitable pharmaceutically acceptable carriers and formulations are described in detail, for example, in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition may be administered by various routes such as oral or parenteral administration to mammals such as rats, mice, livestock, humans, etc., and all manner of administration may be expected, for example, oral, Intravenous, intramuscular, subcutaneous, intrauterine or intracerebroventricular injections.

The pharmaceutical composition is administered in a medically effective amount. In the present invention, a pharmaceutically effective amount means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention. The effective dose level will depend on the type of disease and its severity, Including the age, weight, health and sex of the patient, sensitivity of the patient to the drug, time of administration of the particular extract used, route of administration and rate of release, duration of treatment, Can be determined according to factors well known in the art. Generally, a dose of 0.1 to 1,000 mg / kg, preferably 10 to 100 mg / kg on an adult basis can be administered once to several times per day. When the composition is an external preparation, it is preferable to apply the composition in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day and continue for 1 month or more. However, the scope of the present invention is not limited by the dose.

The pharmaceutical composition may be prepared in a unit dosage form by formulating it together with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art to which the present invention belongs. Into a capacity container. The formulations may be formulated into tablets, capsules, powders, granules, suspensions, emulsions, syrups, emulsions, alerts, ointments, sprayers, oils A tablet, a tincture, a bath, a liniment, a lotion, a patch, a pad, a cream, and the like. In addition, it can be preferably used as an external preparation for skin intended for topical administration for application directly to the affected area. In this case, a form such as an ointment, a lotion, a spray or a gel is preferable. These external preparations for skin may also be included in a support base or matrix or the like, which can be applied directly to the treatment site, and examples of the support substrate include gauze or bandages.

According to one preferred embodiment of the present invention, the present invention provides a cosmetic composition for preventing or improving skin aging comprising an extract of Camellia japonica (Thunb.) Engl as an active ingredient, Wherein the composition is prevented or treated by inhibiting the formation of a final glycation end product by camphor tree mistletoe extract and accelerating decomposition.

The camellia mistletoe extract is preferably 0.001 to 10% by weight based on the total composition. When the content is less than 0.0001% by weight, the effect of inhibiting the formation of AGEs and the activity of decomposing activity is too weak. When the content is more than 10% by weight, the effect of increasing the content is not increased. More preferably, the camellia mist mistake extract contains 0.001 to 5% by weight based on the total composition.

The cosmetic composition according to the present invention may further contain components commonly used in cosmetic compositions in addition to the camellia mistletoe extract. For example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, and carriers may be included. In addition, the cosmetic composition may further include a skin absorption promoting substance to improve the skin whitening effect.

The cosmetic composition may be prepared in any form conventionally produced in the art and may be in the form of, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant- , A powder foundation, an emulsion foundation, a wax foundation, and a spray, but the present invention is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.

When the formulation of the cosmetic composition is a paste, a cream or a gel, the carrier component may be an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide Can be used.

When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of spray, a mixture of chlorofluorohydrocarbons, Propellants such as propane / butane or dimethyl ether.

In the case of the solution or emulsion of the cosmetic composition, a solvent, a solubilizer or an emulsifier is used as a carrier component. Examples of the solvent include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butylene glycol, a glycerol aliphatic ester, a polyethylene glycol, or a fatty acid ester of sorbitan can be used as a solubilizing agent or an emulsifying agent.

When the formulation of the cosmetic composition is in the form of a suspension, the carrier component may be a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum may be used.

When the formulation of the cosmetic composition is an interfacial active agent-containing cleansing agent, it is preferable to use, as carrier components, aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyltaurate, sarcosinates, fatty acids Amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

According to one preferred embodiment of the present invention, the present invention provides a method for preventing diabetic complications, arteriosclerosis, renal insufficiency, rheumatoid arthritis, Alzheimer's disease, skin aging prevention including an effective ingredient of Korthalsella japonica (Thunb.) Engl extract Wherein the inhibition and improvement of the disease and skin aging are prevented or ameliorated by the inhibition of the formation of the final glycation end product and the promotion of degradation by the camellia seed mistletoe extract.

The food composition of the present invention may further contain, as an active ingredient, a camellia mistletoe extract, as well as components that are ordinarily added in the manufacture of food such as proteins, carbohydrates, fats, nutrients, seasonings and flavors.

Examples of such carbohydrates are monosaccharides, such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.

For example, when the food composition of the present invention is prepared as a drink, it additionally contains citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, etc. in addition to the camellia mistletoe extract of the present invention .

The camellia mistletoe extract is preferably 0.001 to 10% by weight based on the total composition. When the content is less than 0.0001% by weight, the effect of inhibiting the formation of AGEs and the activity of decomposing activity are too weak. When the content is more than 10% by weight, the effect of increasing the content is insufficient.

According to one embodiment of the present invention, the present invention provides a method for preventing or treating diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis and one or more diseases selected from the group consisting of Alzheimer's disease using a composition comprising a camellia mistletoe extract ≪ / RTI >

According to one embodiment of the present invention, the present invention relates to a method for preventing or improving skin aging using a composition comprising a camellia mistletoe extract.

On the other hand, since the camellia mistletoe extract of the present invention is a natural substance, it is harmless to the human body and has little toxicity and side effects. Therefore, it can be safely used for long-term use and can be safely applied to the pharmaceutical, have.

As described above, according to the present invention, the camellia mistletoe extract has an effect of inhibiting the production of final glycation end products and cross-linking cleavage effect between the final glycation products and collagen, resulting in diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis or Alzheimer's And the like, and for preventing or ameliorating skin aging.

Fig. 1 is a graph showing the results of comparative evaluation of the cutting efficacy of Camellia pallidum extract against cross-linking of collagen and final glycation products.

Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

Example 1 Evaluation of Effect of Camellia xanthoptera Extract on Inhibition of Ultimate Glycosylation in vitro )

Bovine serum albumin (BSA), 10 mM glyceraldehyde, 1 mM diethylenetriaminepentaacetic acid (DTPA), 0.1 M phosphate buffer (pH 7.4), 0.02% The reaction mixture of sodium azide and camellia mist mist extract was incubated at 37 ° C for 5 days. Aminoguanidine (AG), which is known as a final glycation endogenesis inhibitor, was treated as a positive control. The degree of formation of the final glycation end product is calculated by substituting the fluorescence value measured at Ex = 340 nm / Em = 430 nm using the spectrophotometer into the following equation (1). The results are shown in Table 1 below.

sample Treatment concentration Glycation reaction (%) Control - 100.0 ± 1.6 AG
(ppm) 500 35.3 ± 0.3 Camellia mistletoe extract
(ppm) 500 89.7 ± 1.0 1000 83.3 ± 0.1 2000 72.9 1.4 Mistletoe extract
(ppm) 500 95.3 ± 2.0 1000 98.8 ± 1.5 2000 97.4 ± 1.4 Oak mistletoe extract
(ppm) 500 105.2 ± 2.3 1000 100.3 ± 2.8 2000 99.8 ± 1.6 Camellia sinensis extract
(ppm) 500 97.8 ± 0.5 1000 98.5 ± 1.1 2000 93.0 ± 0.6

As shown in Table 1 above, it can be confirmed that the camellia mistletoe extract has a concentration-dependent effect of inhibiting the final glycation end product. On the other hand, it can be seen that the general mistletoe extract, oak mistletoe extract and camellia sinensis extract do not have the effect of inhibiting the final glycosylation.

Example 2 Evaluation of Cleavage Efficiency of Camellia pallidum Extract against Cross-Linking of Glycated Product and Collagen in vitro )

The final glycosylated product labeled with horseradish peroxidase was dispensed into a collagen-coated 96-well plate and incubated at 37 ° C for 4 hours to cross-link the collagen and the final glycosylation product . After washing with 0.05% PBST for 3 times to remove collagen and unattached final glycation products, ALT-711 and Camellia pallidum extract, well known as the final glycosylated product cross-linking cleavage, were treated at 37 ° C for 16 hours. After washing 3 times with 0.05% PBST, TMB was developed as a substrate and absorbance was measured at 450 nm. The degree of cross-linking between the collagen and the final glycation product is calculated by the following equation (2). The results are shown in Table 2 and FIG.

Fig. 1 is a graph showing the results of comparative evaluation of the cutting efficacy of Camellia pallidum extract against cross-linking of collagen and final glycation products.

sample Treatment concentration Cross-linking ( % ) Control - 100.0 0.0 ALT-711
( mM ) 2 52.1 ± 9.5 Camellia mistletoe  extract
(ppm) One 68.5 ± 7.9 10 27.7 ± 8.5 50 15.2 ± 5.8 Mistletoe extract
(ppm) One 100.3 + 8.9 10 110.4 ± 7.5 50 109.3 ± 9.3 Oak mistletoe extract
(ppm) One 98.3 ± 3.9 10 93.6 ± 15.5 50 107.1 ± 7.0 Camellia sinensis extract
(ppm) One 101.3 ± 3.5 10 100.8 ± 4.2 50 90.3 ± 4.8

As shown in the above Table 2, it can be confirmed that the camellia mistletoe extract showed better cross-linking activity than ALT-711 used as a positive control. Also, although not described in the examples, there was no cross-linking cleavage effect in the common mistletoe and oak mistletoe extracts as opposed to the camellia mistletoe extract.

≪ Example 3 > Crosslinking between the final glycation product and collagen in vivo evaluation

We observed hemoglobin A1C (HbA1c) in the type 2 diabetic model db / db mouse after 4 weeks of placebo and Camellia pallidum extract to prevent diabetic complications. HbA1c, the glycosylated product of hemoglobin, is the most well - known in - body glycation product and is used as an indicator of glycemic control in diabetic patients.

Control: Placebo group treated group

BSDB # 1: 100 mg / kg / day of camellia mistletoe extract

BSDB # 2: Camellia seed mistletoe extract 250 mg / kg / day

Blood HbA1c  ( % ) 1 week 2 weeks 3 weeks 4 weeks Control 6.9 ± 0.7 7.1 ± 0.8 7.3 ± 1.1 7.4 ± 0.8 BSDB  #One 7.0 ± 0.6 6.9 ± 0.9 6.8 ± 0.6 6.4 ± 0.7 BSDB  #2 7.1 ± 1.3 6.8 ± 0.7 6.3 ± 0.8 5.9 ± 0.5

As shown in Table 3, it can be seen that the HbA1c level decreases in a concentration-dependent manner in the group consuming the camellia mistletoe extract compared with the placebo group.

Formulation examples of cosmetic compositions using the composition of the present invention are illustrated below.

Formulation Example 1: Cosmetic preparation

1-1. Softening longevity

ingredient weight% Camellia mistletoe extract 0.05 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 ethanol 10.0 Triethanolamine 0.1 Preservatives, micronutrients, trace fragrances and trace water 82.75 sum 100.0

1-2. Nutritional lotion

ingredient weight% Camellia mistletoe extract 0.05 Wax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 5.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water 69.65 sum 100.0

1-3. Nourishing cream

ingredient weight% Camellia mistletoe extract 0.05 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 10.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water 56.75 sum 100.0

1-4. Massage cream

ingredient weight% Camellia mistletoe extract 0.05 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water 27.45 sum 100.0

1-5. pack

ingredient weight% Camellia mistletoe extract 0.05 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 Allantoin 0.1 ethanol 5.0 Nonyl phenyl ether 0.3 Preservatives, micronutrients, trace fragrances and trace water 81.35 sum 100.0

Formulation Example 2: Preparation of a pharmaceutical preparation

2-1. Manufacture of Powder

ingredient Weight (g) Camellia mistletoe extract 2 Lactose One

The above components were mixed and packed in airtight bags to prepare powders.

2-2. Manufacture of tablets

ingredient Weight (mg) Camellia mistletoe extract 100 Corn starch 100 Lactose 100 Magnesium stearate 2

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

2-3. Preparation of capsules

ingredient Weight (mg) Camellia mistletoe extract 100 Corn starch 100 Lactose 100 Magnesium stearate 2

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

Claims (6)

A pharmaceutical composition for preventing or treating at least one disease selected from the group consisting of diabetic complications, an arteriosclerosis, renal failure, rheumatoid arthritis and Alzheimer's, which comprises an extract of Camellia japonica (Thunb.) Engl as an active ingredient. The method according to claim 1,
Wherein said disease is prevented or treated by inhibiting the formation of a final glycation end product by camellia seed mistletoe extract and accelerating decomposition. A cosmetic composition for preventing or improving skin aging comprising an extract of Camellia japonica (Thunb.) Engl as an active ingredient. The method of claim 3,
Wherein the skin aging is prevented or ameliorated by inhibiting the formation of final glycosylation products and accelerating the degradation by the camellia mist mistletoe extract. At least one disease selected from the group consisting of diabetic complications, an arteriosclerosis, renal failure, rheumatoid arthritis and Alzheimer's which contains an extract of Korthalsella japonica (Thunb.) Engl as an active ingredient, or a food composition for preventing or improving skin aging. 6. The method of claim 5,
Wherein said disease or skin aging is prevented or ameliorated by inhibiting the formation of a final glycation end product by camellia mistletoe extract and promoting its degradation.

Images